Get the Stockscreener App
5.65
0.53%
-0.03
After Hours:
5.68
0.03
+0.53%
Prime Medicine Inc stock is traded at $5.65, with a volume of 3.06M.
It is down -0.53% in the last 24 hours and up +38.82% over the past month.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$5.68
Open:
$5.83
24h Volume:
3.06M
Relative Volume:
0.78
Market Cap:
$760.34M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-2.6037
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
-7.07%
1M Performance:
+38.82%
6M Performance:
+324.81%
1Y Performance:
+55.22%
1-Day Range:
$5.43
$5.90
1-Week Range:
$5.43
$6.85
52-Week Range:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
5.65 | 1.01B | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Downgrade | Citigroup | Buy → Neutral |
| May-20-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Painful Week for Retail Investors Invested in Prime Medicine, Inc. (NASDAQ:PRME) After 6.6% Drop, Institutions Also Suffered Losses - 富途牛牛
Does Prime Medicine Inc. qualify in momentum factor screeningQuarterly Portfolio Report & Growth Focused Entry Reports - newser.com
News impact scoring models applied to Prime Medicine Inc.Weekly Gains Summary & Technical Analysis for Trade Confirmation - newser.com
Why Prime Medicine Inc. stock appeals to analystsWeekly Trend Recap & Community Trade Idea Sharing - newser.com
Quantitative breakdown of Prime Medicine Inc. recent moveTrade Performance Summary & AI Optimized Trade Strategies - newser.com
Trend analysis for Prime Medicine Inc. this weekMarket Activity Summary & Expert Verified Stock Movement Alerts - newser.com
Is Prime Medicine Inc. stock a buy on dips2025 Volatility Report & Weekly High Momentum Picks - newser.com
Prime Medicine, Inc.'s (NASDAQ:PRME) 6.6% loss last week hit both individual investors who own 30% as well as institutions - simplywall.st
Prime Medicine (NASDAQ:PRME) Stock Price Down 5.8%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 3.4%Here's What Happened - MarketBeat
Using AI based signals to follow Prime Medicine Inc.Market Growth Summary & Short-Term Trading Opportunity Alerts - newser.com
Is it too late to sell Prime Medicine Inc.July 2025 Short Interest & Short-Term High Return Strategies - newser.com
Prime Medicine Soars 9.88% to Day High of $6.85 Amid Strong Intraday Performance - Markets Mojo
Is Prime Medicine Inc. stock entering bullish territoryWeekly Stock Report & High Return Trade Guides - newser.com
How to recover losses in Prime Medicine Inc. stockMarket Risk Report & Daily Stock Momentum Reports - newser.com
Volume spikes in Prime Medicine Inc. stock – what they mean2025 Technical Patterns & Long-Term Safe Investment Plans - newser.com
Volatility clustering patterns for Prime Medicine Inc.July 2025 Fed Impact & Low Drawdown Investment Ideas - newser.com
Prime Medicine (NASDAQ:PRME) Stock Price Up 11.6%Should You Buy? - MarketBeat
Prime Medicine (NYSE:PRME) Shares Up 7.8%Still a Buy? - MarketBeat
Prime Medicine, Inc. Hits New 52-Week High of $6.94 - Markets Mojo
Prime Medicine, Inc. Hits New 52-Week High of $6.92 - Markets Mojo
Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire
Prime Medicine (NASDAQ:PRME) Sets New 12-Month HighWhat's Next? - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
What earnings revisions data tells us about Prime Medicine Inc.July 2025 Patterns & Entry and Exit Point Strategies - newser.com
Published on: 2025-10-06 02:45:47 - newser.com
Using flow based indicators on Prime Medicine Inc.Quarterly Market Review & Momentum Based Trading Signals - newser.com
Measuring Prime Medicine Inc.’s beta against major indicesJuly 2025 Earnings & Weekly Chart Analysis and Guides - newser.com
Prime Medicine Stock Price, Quotes and Forecasts | NASDAQ:PRME - Benzinga
Prime Medicine, Inc. Hits New 52-Week High of $5.82 - Markets Mojo
Short interest data insights for Prime Medicine Inc.July 2025 Trends & Stock Portfolio Risk Management - newser.com
Backtesting results for Prime Medicine Inc. trading strategiesJuly 2025 Volume & Smart Investment Allocation Insights - newser.com
Is Prime Medicine Inc a good long term investmentIPO Market Watch & Double Digit Wealth Tips - earlytimes.in
Prime Medicine (NYSE:PRME) Trading Up 8%What's Next? - MarketBeat
Prime Medicine Sees Strong Momentum Among Top Healthcare Stocks - Kalkine Media
Prime Medicine (NASDAQ:PRME) Hits New 1-Year HighTime to Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Up 3.9%Here's Why - MarketBeat
When is the best time to exit Prime Medicine Inc.July 2025 Gainers & Free Reliable Trade Execution Plans - newser.com
Septerna appoints Keith Gottesdiener to board of directors - Investing.com India
Former Prime Medicine CEO and 20+ Drug Approval Leader Keith Gottesdiener Joins Septerna's Board - Stock Titan
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):